Additionally, an increase in de novo fatty acid biogenesis is a metabolic attribute that equips tumours with proliferative and survival benefits, and therefore, FASN (fatty acid synthase) is overexpressed in many cancers, including colon cancer (Schroeder et al. 2021). The gene discussed is FASN; the disease is neoplasm.